Novavax recently slashed its revenues forecasts, but is hoping a two-in-one COVID-19 and flu combination could help it carve out space in the post-pandemic market.
Novavax is to shortly unveil the first data from its combined COVID-19 and influenza vaccine, which it hopes could help establish its products alongside the household names of Pfizer/BioNTech and Moderna vaccines.
The company gained conditional marketing authorization in the EU for its protein nanoparticle-based COVID-19 vaccine, NVX-CoV2373 (known there as Nuvaxovid),...
Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.
Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.
Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.
Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
